Conversely, in PLX-R cells PDH activity does not change whereas the protein levels increase: this data might suggest that the resistant cells become able to counteract the drug-induced inhibition of PDH activity (54) by increasing PDH expression and leading to a metabolic rewiring from glycolysis to OXPHOS that allows melanoma cells to produce sufficient ATP levels and to survive. Here, PDP1 is linked to melanoma.